Research Influenza Partnering 2007-2 by winaarkstore


									|| Research|| Influenza Partnering 2007-2012
The Influenza Partnering 2007-2012 report provides understanding and access to the influenza
partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in influenza partnering deals
Top influenza deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type


 The Influenza Partnering 2007-2012 provides understanding and access to the influenza
partnering deals and agreements entered into by the worlds leading healthcare companies.

 The report provides an analysis of influenza partnering deals. The majority of deals are
discovery or development stage whereby the licensee obtains a right or an option right to license
the licensors influenza technology. These deals tend to be multicomponent, starting with
collaborative R&D, and commercialization of outcomes.

 Understanding the flexibility of a prospective partner?s negotiated deals terms provides critical
insight into the negotiation process in terms of what you can expect to achieve during the
negotiation of terms. Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are triggered ? contract documents
provide this insight where press releases do not.

 This data driven report contains over 280 links to online copies of actual influenza deals and
contract documents as submitted to the Securities Exchange Commission by companies and their
partners, where available. Contract documents provide the answers to numerous questions about
a prospective partner?s flexibility on a wide range of important issues, many of which will have
a significant impact on each party?s ability to derive value from the deal.

The initial chapters of this report provide an orientation of influenza partnering trends.

 Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the
trends in influenza partnering since 2007, including a summary of deals by industry sector, stage
of development, deal type, and technology type. Numerous tables provide outline financial

Browse complete Report on :

Aarkstore Enterprise


Viral Partnering Terms and Agreements
Anthrax Partnering 2007-2012
E.coli Partnering 2007-2012
MRSA Partnering 2007-2012
Sepsis Partnering 2007-2012
Common Cold Partnering 2007-2012
Hepatitis Partnering 2007-2012
Herper simplex Partnering 2007-2012
HIV Partnering 2007-2012
Influenza Partnering 2007-2012
RSV Partnering 2007-2012
Parasitic Partnering 2007-2012
Fungal Partnering 2007-2012
Tropical Disease Partnering 2007-2012
Dengue Fever Partnering 2007-2012
Malaria Partnering 2007-2012
Renal Failure Partnering 2007-2012
Dialysis Partnering 2007-2012
Genitourinary Symptoms Partnering 2007-2012
Chronic Kidney Disease Partnering 2007-2012
Blood Substitute Partnering 2007-2012
Anemia Partnering 2007-2012
Hemophilia Partnering 2007-2012
Hypertension Partnering 2007-2012
Hypercholesterolemia Partnering 2007-2012
Congestive Heart Failure Partnering 2007-2012
Coronary Artery Disease Partnering 2007-2012
Atherosclerosis Partnering 2007-2012
Arrhythmia Partnering 2007-2012
Angina Partnering 2007-2012
Abbott Partnering 2005-2012
Actavis Partnering 2005-2012
Alcon Partnering 2005-2012
Allergan Partnering 2005-2012
Amgen Partnering 2005-2012
Apotex Partnering 2005-2012
Astellas Partnering 2005-2012
AstraZeneca Partnering 2005-2012
Baxter Partnering 2005-2012
Bayer Partnering 2005-2012
Biogen Idec Partnering 2005-2012
Boehringer Ingelheim Partnering 2005-2012
Bristol-Myers Squibb Partnering 2005-2012
Celgene Partnering 2005-2012
Cephalon Partnering 2005-2012
Chugai Partnering 2005-2012
CSL Partnering 2005-2012
Daiichi Sankyo Partnering 2005-2012
Dainippon Sumitomo Partnering 2005-2012

To top